List of Excipients in Branded Drug RELENZA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GlaxoSmithKline LLC	RELENZA	zanamivir	0173-0681	LACTOSE
A-S Medication Solutions	RELENZA	zanamivir	50090-8016	LACTOSE
Physicians Total Care Inc	RELENZA	zanamivir	54868-4377	LACTOSE
Dispensing Solutions Inc	RELENZA	zanamivir	68258-3030	LACTOSE

Relenza Excipient Strategy and Commercial Opportunities

Last updated: August 31, 2026

Relenza contains zanamivir, a neuraminidase inhibitor, delivered as a dry powder through the Diskhaler device. Its core excipient system is simple: lactose monohydrate is the carrier, while the device and blister package control dose delivery. The main commercial opportunities are therefore in lactose engineering, device-compatible reformulation, allergen management, generic or authorized-generic supply, and alternative zanamivir delivery systems.

Relenza's original pharmaceutical and regulatory exclusivities have expired. The principal barriers to competition are formulation-device integration, low-dose blend uniformity, inhalation performance, clinical bridging, and manufacturing controls rather than a strong remaining composition-of-matter patent position.

What excipients are used in Relenza?

Relenza inhalation powder contains zanamivir and lactose monohydrate. The U.S. prescribing information identifies approximately 5 mg of zanamivir and 20 mg of lactose monohydrate per inhaled blister dose. The lactose carrier may contain trace milk proteins, which creates a specific labeling and supply-chain issue for patients with severe milk-protein allergy.[1]

Component	Function	Commercial relevance
Zanamivir	Active antiviral ingredient	Low-dose drug requiring high blend uniformity
Lactose monohydrate	Bulk carrier and powder-flow aid	Controls dispersion, dose consistency and emitted dose
Milk-protein residues associated with lactose	Potential allergen concern	Requires supplier qualification and risk controls
Aluminum blister and foil packaging	Moisture and dose protection	Important for stability and device compatibility
Diskhaler device	Powder deaggregation and delivery	Creates a combination-product and human-factors barrier

The Relenza label does not identify a large excipient package. The commercial performance of the product depends on physical properties such as particle-size distribution, lactose morphology, moisture content, electrostatic behavior and drug-carrier adhesion.

How does lactose function in the Relenza inhalation powder?

Lactose is primarily a carrier, not a conventional tablet filler. Zanamivir particles are blended with lactose and must detach from the carrier during inhalation. The formulation must balance two competing requirements:

1. Sufficient adhesion to prevent segregation during filling and handling.
2. Sufficient detachment during inhalation to produce a respirable zanamivir fraction.

Relevant lactose attributes include:

• Particle-size distribution.
• Fine-particle content.
• Crystallinity and anomeric composition.
• Surface roughness.
• Residual moisture.
• Bulk and tapped density.
• Electrostatic charge.
• Microbial and endotoxin controls.
• Milk-protein residue profile.

A direct replacement with another lactose grade is unlikely to be a simple equivalence exercise. Changes in lactose morphology can alter delivered dose, fine-particle mass, device retention, emitted dose and powder deagglomeration.

Which lactose grades are commercially relevant?

Commercial opportunities exist for inhalation-grade lactose with controlled surface and particle characteristics. The strongest opportunity is not generic lactose supply but a qualified grade engineered for zanamivir or a similar low-dose antiviral powder.

Potential differentiated products include:

• Coarse carrier lactose with controlled fines.
• Spray-dried lactose for improved flow.
• Lactose with reduced electrostatic charging.
• Low-moisture lactose for enhanced stability.
• Milk-protein-controlled lactose for allergen-sensitive supply chains.
• Custom carrier blends optimized for Diskhaler or capsule-based DPI devices.

A supplier would need to demonstrate lot-to-lot consistency and preserve the critical quality attributes established for the reference product.

What formulation patents protect Relenza?

Relenza's original protection was based primarily on zanamivir chemistry, antiviral use and inhaled pharmaceutical formulations. The core U.S. patent estate is now largely expired because the product was first approved in 1999 and the relevant patent terms were generally tied to filings made decades earlier.

The practical patent position is summarized below.

Protection category	Historical relevance	Current commercial effect
Zanamivir composition patents	Protected the active compound and related sialic-acid analogues	Generally expired
Pharmaceutical composition patents	Covered formulations containing zanamivir	Generally expired
Inhalation-use patents	Covered pulmonary or intranasal administration	Generally expired
Diskhaler-related rights	Covered delivery-device or packaging concepts	Any remaining rights are unlikely to block ordinary competition by themselves
Manufacturing-process patents	Could cover specific synthesis or particle-engineering steps	Must be assessed claim by claim
Current formulation patents	Potentially relevant only if later-filed and unexpired	No clear broad blocking position is associated with the original Relenza product

The absence of a strong active-ingredient patent does not eliminate freedom-to-operate risk. A new product using a different inhaler, carrier system, blister architecture or manufacturing method could encounter device, process or formulation patents owned by third parties.

When did Relenza lose exclusivity?

Relenza's key U.S. exclusivity milestones occurred long ago.

Event	Approximate timing	Commercial significance
FDA approval of Relenza	1999	Established U.S. approval for inhaled zanamivir
New chemical entity exclusivity	Expired in 2004	Removed the primary FDA exclusivity block
Core patent term expiration	Generally during the 2010s	Removed most composition-based barriers
Current market position	Post-exclusivity	Competition depends on regulatory, device and manufacturing execution

Relenza is not protected today by the type of active pharmaceutical ingredient exclusivity associated with a recently launched antiviral. Market entry remains difficult because the product is a low-dose dry powder delivered through a dedicated device, not because the original exclusivity period remains intact.

What is the FDA regulatory status of Relenza?

Relenza is an FDA-approved prescription inhalation powder for treatment of acute uncomplicated influenza and for prophylaxis in specified age groups. The labeled treatment population includes adults and children aged 7 years and older. Prophylaxis labeling includes adults and children aged 5 years and older, subject to the current prescribing information.[1]

The FDA-approved dosage form is oral inhalation powder delivered through the Diskhaler. A competitor cannot assume that an orally inhaled zanamivir product will qualify for a straightforward generic pathway if it uses a materially different device or formulation.

Potential regulatory pathways include:

• An abbreviated new drug application for a product sufficiently equivalent to the reference listed drug.
• A 505(b)(2) application for a different device, formulation or delivery route.
• A new drug application for nebulized, nasal or other alternative zanamivir delivery.
• A reformulated product with a new excipient system supported by clinical bridging.

For a dry-powder competitor, the core development package would likely include comparative pharmaceutical performance, delivered-dose testing, aerodynamic particle-size distribution, device performance, stability and, depending on FDA requirements, comparative clinical or pharmacokinetic data.

What generic entry risks exist for Relenza?

The largest generic-entry risks are technical rather than patent-based.

Low-dose blend uniformity

Each dose contains only about 5 mg of zanamivir. Small errors in blending, segregation or powder transfer can create clinically meaningful dose variability. A carrier system designed for a higher-dose inhaled drug may not perform adequately for Relenza.

Device dependence

Relenza's performance is inseparable from the Diskhaler. A generic product using the same or a substantially similar device must address device rights, supply continuity and user-interface equivalence. A different device may reduce intellectual-property exposure but increase regulatory and clinical complexity.

Powder deagglomeration

The emitted dose depends on the patient's inspiratory effort and the powder's deagglomeration behavior. Pediatric and elderly users may generate lower inspiratory flows, creating a commercial disadvantage for a formulation that performs well only under ideal laboratory conditions.

Moisture sensitivity

Moisture can change lactose surface properties, powder cohesion and aerosolization. Blister seal integrity, foil selection and storage conditions are material parts of the formulation strategy.

Milk-protein contamination

Because lactose can contain milk-protein residues, a competitor should qualify suppliers using defined allergen controls. A lower-residue lactose system could support differentiated labeling, but any change would require regulatory and clinical assessment.

Which excipient opportunities have the strongest commercial potential?

The most attractive opportunities are adjacent to, rather than identical to, the original Relenza formulation.

Opportunity	Value proposition	Main barrier
Qualified inhalation-grade lactose	Reliable carrier supply and consistent aerosol performance	Equivalence and supplier qualification
Low-allergen lactose	Addresses milk-protein warning and procurement concerns	Demonstrating clinically relevant benefit
Optimized carrier morphology	Improves emitted dose and respirable fraction	Patent and process freedom to operate
Alternative DPI platform	Avoids dependence on Diskhaler supply	New device and human-factors work
Unit-dose capsule product	Uses established capsule-DPI manufacturing infrastructure	Regulatory bridging and device compatibility
Moisture-resistant packaging	Extends stability and reduces transport losses	Packaging validation
Ready-to-use emergency stockpile product	Supports government and institutional procurement	Demand uncertainty and shelf-life requirements
Pediatric or low-flow optimized product	Improves usability in vulnerable populations	Clinical and human-factors evidence

Government influenza stockpiles could create episodic demand for zanamivir products, particularly where resistance to oseltamivir is a procurement concern or where supply diversification is required. The commercial model would likely depend on tender awards and preparedness contracts rather than routine retail volume.

How does Relenza compare with Tamiflu and Xofluza?

Relenza competes with oral oseltamivir, marketed as Tamiflu and available in generic form, and baloxavir marboxil, marketed as Xofluza.

Product	Active ingredient	Dosage form	Excipient and device implications	Competitive position
Relenza	Zanamivir	Dry powder inhaler	Lactose carrier and dedicated Diskhaler	Differentiated route, but device and inhalation burden
Tamiflu	Oseltamivir	Capsule and oral suspension	Conventional oral excipient systems	Broad generic competition and easier administration
Xofluza	Baloxavir marboxil	Oral tablet and granules in some markets	Oral solid dosage manufacturing	Single-dose convenience and newer product positioning

Relenza's inhaled route can be commercially useful when oral administration is unsuitable or when resistance and treatment guidelines favor an alternative. Its route also limits adoption because patients with airway disease may experience bronchospasm risk, and correct inhaler technique is required.[1]

What licensing deals affect Relenza?

Zanamivir originated from research associated with Biota Pharmaceuticals and was licensed to Glaxo, later part of GSK, for development and commercialization. The relationship generated disputes over commercialization and royalty obligations, which were resolved through legal proceedings and settlement activity reported in the public record.

The licensing history matters for diligence because rights to:

• Zanamivir manufacturing know-how.
• Historical clinical data.
• Device technology.
• International regulatory files.
• Trademark and legacy product materials.

may not reside with the same entity. A party seeking to commercialize an authorized generic, reformulation or regional product would need to distinguish expired patent rights from continuing contractual, data, trademark and know-how rights.

What patent litigation affects Relenza?

Relenza's most significant historic disputes concerned commercialization and licensing economics rather than a current wave of Paragraph IV litigation. Publicly reported litigation involving Biota and GSK focused on alleged under-commercialization and related contractual obligations.

There is no major current U.S. patent-litigation pattern comparable to the active disputes surrounding newer blockbuster drugs. For a new entrant, the principal legal risks are more likely to involve:

• Device patent claims.
• Inhaler operating mechanisms.
• Blister and dose-metering systems.
• Particle-engineering processes.
• Trade secrets concerning blending and filling.
• Trademark restrictions on the Relenza name.
• Contractual access to historical regulatory or clinical data.

What is the Orange Book status of Relenza?

Relenza's original FDA exclusivity and core patent barriers have expired. The product is therefore a post-exclusivity reference product. The Orange Book remains relevant for identifying any listed patents associated with the reference product, but the commercial assessment is that Relenza does not present a modern, broad composition-of-matter barrier to generic development.[2]

A Paragraph IV challenger would need to evaluate each listed patent, if any remain relevant, and certify that the patent is invalid, unenforceable or not infringed. Given the age of the product, a filing strategy would more likely focus on abbreviated approval, device equivalence and technical performance than on defeating a high-value unexpired compound patent.

How strong is the Relenza patent estate?

The estate is weak for blocking the active ingredient and moderate for technical implementation.

Estate segment	Relative strength today	Reason
Zanamivir composition	Low	Historical patents have expired
Basic influenza treatment method	Low	Long-established use claims are unlikely to block entry
Inhalation formulation	Low to moderate	Scope depends on surviving claims and claim construction
Diskhaler device	Moderate in historical terms	Device-specific rights may affect copying
Manufacturing know-how	Moderate	Trade secrets can remain valuable after patent expiry
New carrier or DPI improvements	Potentially strong	New patent filings can protect differentiated implementation

A competitor should pursue independent formulation and device development rather than reproduce every technical element of the legacy product. That approach can reduce dependence on historical rights and create a new patent position around carrier morphology, dose uniformity, moisture control or low-flow performance.

What generic launch scenarios are commercially realistic?

Three launch models are realistic.

Same-device generic

This model targets the closest possible pharmaceutical and device equivalence. It may reduce clinical risk but creates dependence on a specialized delivery platform and increases device-related freedom-to-operate issues.

Alternative dry-powder inhaler

A different inhaler can support a new device and formulation patent position. The tradeoff is a larger regulatory package and the need to establish usability, dose delivery and clinical comparability.

Non-DPI zanamivir product

Nebulized or intranasal zanamivir could address patients unable to use a Diskhaler. It would be a 505(b)(2) or full NDA-style development opportunity rather than a conventional generic substitution. The clinical value proposition would need to outweigh development cost and competition from oral antivirals.

Key Takeaways

• Relenza's principal excipient is lactose monohydrate, used as a dry-powder carrier.
• The formulation contains approximately 5 mg of zanamivir and 20 mg of lactose per dose.
• Milk-protein residues associated with lactose create a specific allergen and supplier-control issue.
• Relenza's core compound and early formulation exclusivities have expired.
• The strongest remaining barriers are dose uniformity, aerosol performance, device integration, moisture control and manufacturing know-how.
• Commercial opportunities include inhalation-grade lactose, low-allergen carrier systems, alternative DPI devices, improved packaging and non-DPI zanamivir products.
• A same-device generic may have the lowest regulatory risk but the highest dependence on legacy device technology.
• An alternative-device or alternative-route product could generate stronger intellectual-property protection but would require more regulatory and clinical work.
• Relenza competes with generic oseltamivir and newer oral baloxavir, making convenience and targeted use cases central to commercial positioning.
• Licensing, historical clinical data and manufacturing know-how should be separated from expired patent rights in any transaction.

FAQs

Can lactose be replaced in a generic Relenza product?

Yes, but the replacement would need to preserve dose uniformity, emitted dose, aerodynamic particle-size distribution, stability and clinical performance. A non-lactose carrier could increase development and regulatory complexity.

Does Relenza have a biosimilar risk?

No. Relenza is a small-molecule drug, not a biologic. The relevant competitive pathway is generic or 505(b)(2) approval, not biosimilar approval.

Could a new Relenza formulation receive new patent protection?

Yes. New patents could potentially cover a novel carrier system, inhaler, blister configuration, particle-engineering method, stability improvement or alternative delivery route. The claims would need to provide a technical distinction over the extensive prior art surrounding inhaled zanamivir.

Is a Diskhaler required for all zanamivir products?

No. The FDA-approved Relenza product uses the Diskhaler, but a new product could use another delivery system. A different device would likely require additional regulatory, usability and performance evidence.

Is an authorized generic likely to be more attractive than a new zanamivir formulation?

An authorized generic could have lower development risk if it uses an established product and device. A new formulation offers greater differentiation and potential patent value but faces higher regulatory, manufacturing and commercial risk.

References

1. U.S. Food and Drug Administration. (2023). Relenza (zanamivir) inhalation powder: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (1999). Relenza approval letter and regulatory review materials.
4. European Medicines Agency. (n.d.). Relenza: European public assessment and product information.
5. Biota Holdings Limited. (2013). Annual report and disclosures concerning zanamivir licensing and GSK proceedings.